CapsoVision (CV) Stock Price

CapsoVision Price

NYSE·CLOSED
6.65
​
Market closed

Over the last 2 years CapsoVision grew revenue by 17.9% annually, reaching 13.55 M USD. For CapsoVision, the net margin of -186.8% is down versus -115.9% a few years ago. The consensus 12-month price target for CapsoVision is 10.71 USD, about 61.1% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.

CapsoVision stock price

Access this data via the Eulerpool API

CapsoVision business model & stock analysis

CapsoVision, Inc. operates as a commercial-stage medical technology company. The company is headquartered in Saratoga California, California. The company went IPO on 2025-07-02. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.

Frequently asked questions about CapsoVision

Analysts currently set an average price target of 10.71 USD for the CapsoVision stock (median: 10.71 USD), implying +61.1 % versus the latest price. The consensus is based on 10 analyst ratings.

10 analysts currently rate the CapsoVision stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CapsoVision to generate revenue of 14.78 M USD and earnings per share of -0.56 USD.

Converted at the current exchange rate, the CapsoVision share trades at 5.93 EUR (6.65 USD).

The expected revenue of CapsoVision is 14.78 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CapsoVision is -26.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CapsoVision is currently -11.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CapsoVision stock.

The price-to-sales ratio (P/S) of CapsoVision is currently 21.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CapsoVision stock.

The Eulerpool Quality Score for CapsoVision is 2/10.

The ISIN of CapsoVision is US1409351079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CapsoVision is CV. The ticker symbol is used to trade CapsoVision shares on the stock exchange.

Fair ValueTerminal
7.05 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
136,909.09 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 2, 2025
ISIN
US1409351079
Cusip
140935107
Market capitalization
311.49 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-11.96
P/Ee 2027
-14.88
P/Ee 2028
-47.83
P/Ee 2029
22.93
P/Se
21.22
EV/EBIT
—
P/B Ratio
23.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-185.19 %
Last updated Oct 10, 2026, 5:04 PM

CapsoVision Peer Group

All fundamentals and in-depth analysis of CapsoVision

Our stock analysis for CapsoVision stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CapsoVision. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.